June 12, 2018 / 5:13 AM / 4 months ago

BRIEF-Santhera Submits NDA In South Korea For Raxone For The Treatment Of LHON

June 12 (Reuters) - Santhera Pharmaceuticals Holding AG :

* SANTHERA SUBMITS NDA IN SOUTH KOREA FOR RAXONE® FOR THE TREATMENT OF LHON

* RAXONE WAS GRANTED ORPHAN DRUG DESIGNATION FOR LHON IN SOUTH KOREA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below